These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 8766548

  • 1. Semi-allogeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness.
    Roelen DL, Dover EL, Niimi M, Young NT, Morris PJ, Wood KJ.
    Eur J Immunol; 1996 Jul; 26(7):1468-74. PubMed ID: 8766548
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. Induction of indefinite survival of fully allogeneic cardiac grafts and generation of regulatory cells by intratracheal delivery of alloantigens under blockade of the CD40 pathway.
    Uchida N, Shirasugi N, Akiyama Y, Matsumoto K, Shimazu M, Kitajima M, Hamano K, Aramaki O, Ikeda Y, Niimi M.
    Transplantation; 2003 Mar 27; 75(6):878-84. PubMed ID: 12660518
    [Abstract] [Full Text] [Related]

  • 4. Differences in non-MHC alloantigens promote tissue rejection but fail to mediate allogeneic co-operation and autoimmunity in mice neonatally injected with semi-allogeneic F1 B cells.
    Ramos A, Merino R, Merino J.
    Immunology; 1994 Jun 27; 82(2):287-93. PubMed ID: 7927500
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Graft persistence effectively induces and maintains donor-specific unresponsiveness.
    Nishinaka H, Nakafusa Y, Hirano T, Takeda K, Kawano R, Nakano M, Arima T, Nakamura K, Kamei T, Tanaka M.
    J Surg Res; 1997 Mar 27; 68(2):145-52. PubMed ID: 9184673
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Donor bone marrow cells play a role in the prevention of accelerated graft rejection induced by semi-allogeneic spleen cells in transplantation.
    de Moraes LV, Bueno V, Marguti I, Martins GA, Vallochi AL, Yamamoto GL, Panajotopoulos N, Mengel JO, Rizzo LV.
    Transpl Immunol; 2008 Feb 27; 18(4):330-7. PubMed ID: 18158119
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Induction of operational tolerance by random blood transfusion combined with anti-CD4 antibody therapy. A protocol with significant clinical potential.
    Bushell A, Morris PJ, Wood KJ.
    Transplantation; 1994 Jul 27; 58(2):133-9. PubMed ID: 8042231
    [Abstract] [Full Text] [Related]

  • 13. Differential susceptibility of cytotoxic and helper T cell precursors to neonatal tolerization to histocompatibility antigens.
    Ishizaka ST, Carnaud C, Stutman O.
    J Immunol; 1986 Oct 01; 137(7):2093-9. PubMed ID: 2944947
    [Abstract] [Full Text] [Related]

  • 14. Autoimmunity following neonatal tolerance to alloantigens: role of donor I-A and I-E molecules.
    Kramar G, Schurmans S, Berney M, Izui S, del Giudice G, Lambert PH.
    J Autoimmun; 1995 Apr 01; 8(2):177-92. PubMed ID: 7612147
    [Abstract] [Full Text] [Related]

  • 15. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes.
    Madsen JC, Superina RA, Wood KJ, Morris PJ.
    Nature; 1988 Mar 10; 332(6160):161-4. PubMed ID: 3279318
    [Abstract] [Full Text] [Related]

  • 16. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Mar 10; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bidirectional blockade of CD4 and major histocompatibility complex class II molecules: an effective immunosuppressive treatment in the mouse heart transplantation model.
    Ito H, Hamano K, Fukumoto T, Wood KJ, Esato K.
    J Heart Lung Transplant; 1998 May 10; 17(5):460-9. PubMed ID: 9628564
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.